Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe

Recruiting now

Conditions studied: Cancer

In brief

This is an open-label positron emission tomography/computed tomography (PET/CT) study to investigate the clinical predictive value of 68Ga-DOTA-BPP in subjects with triple-negative breast cancer. The visual and semiquantitative methods will be used to assess the PET/CT images

Key facts

Study ID

NCT06203119

Run by

Peking University Cancer Hospital & Institute

People needed

20

Starts

2024-01-02

Expected to finish

2026-12-02

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18-75 years old;
• ECOG score 0 or 1 point;
• Participants with confirmed TNBC cancer who are suggested by the clinicians to conduct PET/CT imaging for tumor diagnosis or staging.

You may not qualify if…

• Pregnant or nursing;
• Severe hepatic or renal dysfunction;
• Low WBC (less than 3 x 10\^9/L);
• Unable to comply with the PET/CT imaging procedures

Where it is running

• Ethics Committee of Peking University Cancer Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.